In principle, the quantitative detection of the activity of TOP1 from humans or from human pathogens enabled by REEAD provides an attractive platform for screening of new compounds with potential clinical relevance for treatment of e.g., cancer or infectious diseases. This evidence concerns the gene TOP1 and cancer.